Cargando…
EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA
Ependymoma (EPN) of childhood is curable in only 50% of cases, with recurrences in the remainder that are refractory to treatment. In recent years significant advances have been made in understanding the molecular and cellular biology of EPN. Recent studies show that PFA subgroup EPN are comprised o...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168184/ http://dx.doi.org/10.1093/neuonc/noab090.061 |
_version_ | 1783701837941047296 |
---|---|
author | Donson, Andrew Ritzmann, Timothy Willard, Nicholas Griesinger, Andrea Amani, Vladimir Harris, Faith Grimaldo, Enrique Sanford, Bridget Riemondy, Kent Hankinson, Todd Grundy, Richard Foreman, Nicholas |
author_facet | Donson, Andrew Ritzmann, Timothy Willard, Nicholas Griesinger, Andrea Amani, Vladimir Harris, Faith Grimaldo, Enrique Sanford, Bridget Riemondy, Kent Hankinson, Todd Grundy, Richard Foreman, Nicholas |
author_sort | Donson, Andrew |
collection | PubMed |
description | Ependymoma (EPN) of childhood is curable in only 50% of cases, with recurrences in the remainder that are refractory to treatment. In recent years significant advances have been made in understanding the molecular and cellular biology of EPN. Recent studies show that PFA subgroup EPN are comprised of multiple neoplastic subpopulations that show undifferentiated, differentiated and mesenchymal characteristics. These studies focused on tumor at presentation, with recurrent EPN being less well understood. In the present longitudinal study we examine changes in neoplastic cell heterogeneity in serial presentations of PFA EPN using deconvolution (Cibersort) of bulk RNAseq data. Analysis of a cohort of 48 PFA EPN presenting at Children’s Colorado showed survival and PFA1/PFA2 subtype assignment was associated with the proportion of individual neoplastic subpopulations as determined by deconvolution. Tumors that subsequently regrew had a significantly higher estimated proportion of undifferentiated EPN cells (UEC) at presentation, than those that were non-recurrent after 5 years follow-up. This outcome association potentially age related, as UEC proportions are significantly higher in PFA arising in children < 1 year old who have a particularly poor prognosis. Changes in PFA neoplastic subpopulations at recurrence was performed in two cohorts of patients from Children’s Colorado (n=23) and Nottingham, UK (n=15). As a whole, no subpopulation proportion was significantly changed at recurrence. However, separation of PFA into subtypes PFA1 and PFA2 revealed an increase in the proportion of the cilia-differentiated EPN cell subpopulation is more frequent event in PFA1 (15/24), and rare in PFA2 (2/11). Changes in other neoplastic subpopulations at recurrence were smaller and only seen in PFA1, both UEC and mesenchymal subpopulations being lower at recurrence. In summary, only PFA1 showed dynamic changes in neoplastic subpopulation proportions at recurrence, with potential impacts on transcriptomic based-subgroup assignment, whereas PFA2 proportions remained largely stable. |
format | Online Article Text |
id | pubmed-8168184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-81681842021-06-02 EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA Donson, Andrew Ritzmann, Timothy Willard, Nicholas Griesinger, Andrea Amani, Vladimir Harris, Faith Grimaldo, Enrique Sanford, Bridget Riemondy, Kent Hankinson, Todd Grundy, Richard Foreman, Nicholas Neuro Oncol Ependymoma Ependymoma (EPN) of childhood is curable in only 50% of cases, with recurrences in the remainder that are refractory to treatment. In recent years significant advances have been made in understanding the molecular and cellular biology of EPN. Recent studies show that PFA subgroup EPN are comprised of multiple neoplastic subpopulations that show undifferentiated, differentiated and mesenchymal characteristics. These studies focused on tumor at presentation, with recurrent EPN being less well understood. In the present longitudinal study we examine changes in neoplastic cell heterogeneity in serial presentations of PFA EPN using deconvolution (Cibersort) of bulk RNAseq data. Analysis of a cohort of 48 PFA EPN presenting at Children’s Colorado showed survival and PFA1/PFA2 subtype assignment was associated with the proportion of individual neoplastic subpopulations as determined by deconvolution. Tumors that subsequently regrew had a significantly higher estimated proportion of undifferentiated EPN cells (UEC) at presentation, than those that were non-recurrent after 5 years follow-up. This outcome association potentially age related, as UEC proportions are significantly higher in PFA arising in children < 1 year old who have a particularly poor prognosis. Changes in PFA neoplastic subpopulations at recurrence was performed in two cohorts of patients from Children’s Colorado (n=23) and Nottingham, UK (n=15). As a whole, no subpopulation proportion was significantly changed at recurrence. However, separation of PFA into subtypes PFA1 and PFA2 revealed an increase in the proportion of the cilia-differentiated EPN cell subpopulation is more frequent event in PFA1 (15/24), and rare in PFA2 (2/11). Changes in other neoplastic subpopulations at recurrence were smaller and only seen in PFA1, both UEC and mesenchymal subpopulations being lower at recurrence. In summary, only PFA1 showed dynamic changes in neoplastic subpopulation proportions at recurrence, with potential impacts on transcriptomic based-subgroup assignment, whereas PFA2 proportions remained largely stable. Oxford University Press 2021-06-01 /pmc/articles/PMC8168184/ http://dx.doi.org/10.1093/neuonc/noab090.061 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Ependymoma Donson, Andrew Ritzmann, Timothy Willard, Nicholas Griesinger, Andrea Amani, Vladimir Harris, Faith Grimaldo, Enrique Sanford, Bridget Riemondy, Kent Hankinson, Todd Grundy, Richard Foreman, Nicholas EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA |
title | EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA |
title_full | EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA |
title_fullStr | EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA |
title_full_unstemmed | EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA |
title_short | EPEN-11. TUMOR DIFFERENTIATION IMPACTS THE BIOLOGY OF RECURRENCE IN CHILDHOOD POSTERIOR FOSSA EPENDYMOMA |
title_sort | epen-11. tumor differentiation impacts the biology of recurrence in childhood posterior fossa ependymoma |
topic | Ependymoma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168184/ http://dx.doi.org/10.1093/neuonc/noab090.061 |
work_keys_str_mv | AT donsonandrew epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT ritzmanntimothy epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT willardnicholas epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT griesingerandrea epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT amanivladimir epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT harrisfaith epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT grimaldoenrique epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT sanfordbridget epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT riemondykent epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT hankinsontodd epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT grundyrichard epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma AT foremannicholas epen11tumordifferentiationimpactsthebiologyofrecurrenceinchildhoodposteriorfossaependymoma |